Education
About Us
Working with TipRanks
Follow Us
Verastem (VSTM)
NASDAQ:VSTM
VSTM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.10 - $13.52
Previous CloseN/A
Volume547.29K
Average Volume (3M)1.00M
Market Cap
$246.12M
Enterprise Value$205.26M
Total Cash (Recent Filing)$20.95M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.08
Next Earnings
May 08, 2025EPS Estimate
-0.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.49
Shares Outstanding51,489,998
10 Day Avg. Volume1,058,263
30 Day Avg. Volume1,002,289
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)29.60
Price to Cash Flow (P/CF)-3.10
P/FCF Ratio0.00
Enterprise Value/Market Cap0.83
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit20.53
Enterprise Value/Ebitda-1.47
Forecast
1Y Price Target
$12.67Price Target Upside163.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
---
Verastem News
PremiumCompany Announcements
Verastem Oncology Reports Progress in Cancer Treatments---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceRecent debt refinancing and new credit facilities are seen positively, as they improve VSTM's financial stability and extend its cash runway.
Market PerformanceThe stock has shown strong momentum, with shares up approximately 50% since the recent price target upgrade, outperforming the XBI index.
Regulatory ApprovalIf approved, the combination of avutometinib and defactinib would become the first drug ever approved for low-grade serous ovarian cancer, marking a significant achievement for the company.
Bears Say
Market StrategyThe company's focus on marketing to the top 100 treatment centers in the country indicates a targeted but limited initial reach for product launch.
Regulatory ChallengesVSTM shares are down approximately 20% due to the news that the company will initially seek approval only in KRAS-mutant patients, not KRAS-wild-type patients.
---
Ownership Overview
1.40% Insiders
7.35% Mutual Funds
42.49% Other Institutional Investors
39.89% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VSTM FAQ
What was Verastem’s price range in the past 12 months?
Verastem lowest stock price was $2.10 and its highest was $13.52 in the past 12 months.
What is Verastem’s market cap?
Verastem’s market cap is $246.12M.
When is Verastem’s upcoming earnings report date?
Verastem’s upcoming earnings report date is May 08, 2025 which is in 22 days.
How were Verastem’s earnings last quarter?
Verastem released its earnings results on Mar 20, 2025. The company reported -$1.33 earnings per share for the quarter, missing the consensus estimate of -$0.829 by -$0.501.
Is Verastem overvalued?
According to Wall Street analysts Verastem’s price is currently Undervalued.
Does Verastem pay dividends?
Verastem does not currently pay dividends.
What is Verastem’s EPS estimate?
Verastem’s EPS estimate is -0.67.
How many shares outstanding does Verastem have?
Verastem has 51,489,998 shares outstanding.
What happened to Verastem’s price movement after its last earnings report?
Verastem reported an EPS of -$1.33 in its last earnings report, missing expectations of -$0.829. Following the earnings report the stock price went down -2.493%.
Which hedge fund is a major shareholder of Verastem?
Currently, no hedge funds are holding shares in VSTM
---
Verastem Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.67 (163.41% Upside)
$12.67 (163.41% Upside)
Blogger Sentiment
Bullish
VSTM Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 723.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $13.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 1.0%
Last 30 Days ▼ 1.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-57.69%
12-Months-Change
Fundamentals
Return on Equity
-526.33%
Trailing 12-Months
Asset Growth
-32.18%
Trailing 12-Months
Company Description
Verastem
Verastem, Inc. (VSTM) is a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life for cancer patients. The company primarily operates in the oncology sector, with a strong emphasis on targeting malignant cells and the tumor microenvironment. Its core products and services revolve around innovative therapies for cancer treatment, particularly targeting specific pathways involved in cancer cell proliferation and survival.
---
VSTM Stock 12 Month Forecast
Average Price Target
$12.67
▲(163.41% Upside)
Technical Analysis
Rigel
―
Astria Therapeutics
―
Personalis
―
Aura Biosciences Inc
―
Amylyx Pharmaceuticals Inc
―
Best Analysts Covering VSTM
1 Year
1 Year Success Rate
4/10 ratings generated profit
1 Year Average Return
-12.58%
assigned a buy rating 6 months ago
Copying Srikripa Devarakonda's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -12.58% per trade.
---